← Back to stories

Abbott Agrees to $385 Million Settlement Over Baby Formula Plant Closure

businesshealthSignificance: 5/10

The Facts

Abbott Laboratories has agreed to pay $385 million to settle claims brought by the U.S. Department of Justice related to the manufacturing practices and 2022 recall of powdered infant formula at its Michigan facility. The settlement resolves a federal investigation and lawsuit tied to the closure of Abbott's Sturgis, Michigan plant, which was the largest baby formula manufacturing facility in the United States. The plant's closure in 2022 contributed to a significant nationwide baby formula shortage.

How different outlets are framing this

With only a single source available — ABC News (US) — a full multi-outlet framing comparison is not possible. However, the ABC News report frames the story primarily through a legal and corporate accountability lens, leading with the dollar figure of the settlement and emphasising the role of the Justice Department in bringing the case. This framing positions Abbott as a company being held to account by federal authorities, rather than foregrounding the consumer impact or the public health dimensions of the 2022 shortage, which affected families across the country.

Notably absent from the available coverage are perspectives from consumer advocacy groups, affected families, or public health experts, which might have shifted the framing toward the human cost of the formula shortage. Similarly, there is no visible framing from international outlets, which might have contextualised the story within broader debates about food supply chain regulation or the concentration of infant formula production among a small number of manufacturers. The single available article provides a factual, institutionally-focused account without deeper interrogation of regulatory failures that allowed the situation to develop.

Source Articles